Henrik Nagel

Tubus Technology is the company behind the TubusOne™ product. TubusOne™ is an easy-to-use communication device used for navigating on tablets and smartphones. Designed specifically for individuals with disabled hand movement. Tubus Technology was established in October 2015 and TubusOne™ was invented in September 2013 and fine-tuned until its launch in 2015. TubusOne™ enables people with low or no functionality in arms and hands to navigate on touchpad devices without any help from other people. TubusOne™ creates independence for people with mobility disabilities, so they can manage their activities on tablets and smartphones without any help from others - from handling their own economy online, to writing e-mails and text messages to playing online games and more - TubusOne™ is independence.

The new contraception method - simple and reversible sterilisation for men. Today, 27% of men worldwide use contraception in one form or another. Many users of contraception ask for an alternative to existing forms e.g. condom, birth control pills or surgery (vasectomy). VasDeBlock is an alternative male contraception method that neither requires surgery nor holds hormones and which is far more practical than condoms. The method is simple and has a significantly lower cost than surgery. Another big advantage is that the fertility quite easily may be restablished.  VasDeBlock medical ApS has consulted with doctors in urology and medical device companies to devise a unique way to temporarily stop male fertility by blocking vas deferens and later to restablish normal fertility relatively easy. Doctors specializing in urology have not identified any basic flaws in the method and assume that it can be used in practice by all males.  In the Western world, the method must be seen as an alternative to well-known methods of contraception, including surgery which 2-5 million men and 6-10 million women undergo yearly. The company is right now in a phase where the focus is on developing prototypes and conduct in-vivo testing to prove the concept. We are looking for financing from sources willing to contribute to the next steps. Financing may be in the form of grants, loans or direct investments.

Tubus Technology is the company behind the TubusOne™ product. TubusOne™ is an easy-to-use communication device used for navigating on tablets and smartphones. Designed specifically for individuals with disabled hand movement. Tubus Technology was established in October 2015 and TubusOne™ was invented in September 2013 and fine-tuned until its launch in 2015. TubusOne™ enables people with low or no functionality in arms and hands to navigate on touchpad devices without any help from other people. TubusOne™ creates independence for people with mobility disabilities, so they can manage their activities on tablets and smartphones without any help from others - from handling their own economy online, to writing e-mails and text messages to playing online games and more - TubusOne™ is independence.

EYE-GO A/S is a Danish MedTech start-up established 2015 based on the work by two designers wanting to develop eye-care technologies that improve the quality of life of people around the world suffering from severe and chronic eye conditions. Problem: Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye drop bottles. Users experience difficulties instilling the medication, over-dose due to drop size, side-effects and may abandon prescribed treatment plan leading to poor disease management. This is not just an issue for patients who best case loose quality of life and worst case may end up blind, but also for pharma companies whose drugs don’t have full therapeutic effect, and society ending up with unnecessary high health care spending. Solution: MistGo® is a new generation micro-dosing drug delivery system mitigating the imperfections with current eye-drop bottles. MistGo® makes it simple and comfortable to self-administer the drug correctly with the precisely required amount of drug entering the eye at first go, and helps patients adhere to treatment long-term This cutting-edge eye treatment technology from EYE-GO is suitable for long-term eye care diseases requiring topical ocular treatment and is compatible with preservative-free liquids. Leading ophthalmologists and frontrunning international industry players have already name it an “an ophthalmologic game changer”. Visit our website to learn more, or contact us now on HNA@EYE-GO.com (Henrik Nagel, CEO) or RS@EYE-GO.com (Rie Saabye, Director Business Development) to discuss licensing opportunities of an innovative drug delivery system for one or more of your innovative substances.

The new contraception method - simple and reversible sterilisation for men. Today, 27% of men worldwide use contraception in one form or another. Many users of contraception ask for an alternative to existing forms e.g. condom, birth control pills or surgery (vasectomy). VasDeBlock is an alternative male contraception method that neither requires surgery nor holds hormones and which is far more practical than condoms. The method is simple and has a significantly lower cost than surgery. Another big advantage is that the fertility quite easily may be restablished.  VasDeBlock medical ApS has consulted with doctors in urology and medical device companies to devise a unique way to temporarily stop male fertility by blocking vas deferens and later to restablish normal fertility relatively easy. Doctors specializing in urology have not identified any basic flaws in the method and assume that it can be used in practice by all males.  In the Western world, the method must be seen as an alternative to well-known methods of contraception, including surgery which 2-5 million men and 6-10 million women undergo yearly. The company is right now in a phase where the focus is on developing prototypes and conduct in-vivo testing to prove the concept. We are looking for financing from sources willing to contribute to the next steps. Financing may be in the form of grants, loans or direct investments.